Alessandro Monopoli
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseases.
Journal: Frontiers in immunology
Published: February 04, 2026
Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis.
Journal: Frontiers in immunology
Published: March 07, 2025
Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Mycosis Fungoides.
Journal: Diagnostics (Basel, Switzerland)
Published: May 05, 2023
Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.
Journal: The Journal of investigative dermatology
Published: August 01, 2021
Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
Journal: Dermatologic therapy
Published: June 13, 2021
Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Journal: Frontiers in immunology
Published: July 03, 2020
Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma.
Journal: The Journal of investigative dermatology
Published: May 20, 2019
Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Journal: Cell death & disease
Published: August 16, 2018
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
Journal: Leukemia
Published: June 27, 2018
Paraneoplastic Epidermolysis Bullosa Acquisita Associated with Thyroid Carcinoma.
Journal: Acta dermato-venereologica
Published: August 26, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026